- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05992935
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
April 26, 2024 updated by: ModernaTX, Inc.
A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
The purpose of the Phase 1 Part of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age.
The purpose of the Phase 2 Part of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants 18 to 80 years of age.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
1260
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Moderna Clinical Trials Support Center
- Phone Number: 1-877-777-7187
- Email: clinicaltrials@modernatx.com
Study Locations
-
-
California
-
Long Beach, California, United States, 90815
- Recruiting
- ARK Clinical Research, LLC
-
-
Colorado
-
Longmont, Colorado, United States, 80501
- Recruiting
- Tekton Research, Inc - Longmont Center
-
-
Florida
-
Hollywood, Florida, United States, 33024
- Recruiting
- Research Centers of America
-
-
Georgia
-
Decatur, Georgia, United States, 30030
- Recruiting
- Accel Research Sites Network
-
-
Illinois
-
Peoria, Illinois, United States, 61614
- Recruiting
- Optimal Research
-
-
Indiana
-
Meridian Hills, Indiana, United States, 83642
- Recruiting
- Velocity Clinical Research - Boise
-
-
Iowa
-
Sioux City, Iowa, United States, 51106
- Recruiting
- Meridian Clinical Research, LLC
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Recruiting
- Johnson County Clin-Trials (JCCT)
-
-
Maryland
-
Rockville, Maryland, United States, 20854
- Recruiting
- Rockville Internal Medicine Group
-
-
Nebraska
-
Norfolk, Nebraska, United States, 68701
- Recruiting
- Meridian Clinical Research, LLC
-
Omaha, Nebraska, United States, 68134
- Recruiting
- Velocity Clinical Research
-
-
New York
-
Rochester, New York, United States, 14609
- Recruiting
- Rochester Clinical Research, Inc
-
-
Texas
-
Houston, Texas, United States, 77054
- Withdrawn
- C & R Research Services USA / HHBA Health LLC
-
Red Oak, Texas, United States, 75154
- Recruiting
- Epic Medical Research, LLC
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- Recruiting
- JBR Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Key Inclusion Criteria:
- Phase 1 Part: Adults 18 to 49 years of age at the time of consent or adults 60 to 80 years of age at the time of consent.
- Phase 2 Part: Adults 18 to 80 years of age at the time of consent.
- Body mass index of 18 to 39 kilogram/meter^2 (inclusive) at the Screening Visit.
- Participants assigned female at birth are eligible to participate if they are not pregnant or breast/chest/body feeding.
- A person of childbearing potential is using a highly effective contraceptive method.
- Participant has provided written informed consent for participation in this study,
Key Exclusion Criteria:
- Is acutely ill or febrile (temperature ≥38.0°C [100.4°F]) 72 hours prior to or at the Screening Visit or Day 1
- History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
- Has a medical, psychiatric, or occupational condition, including reported history of substance abuse, that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment.
- Has a current or previous diagnosis of immunosuppressive condition, to include human immunodeficiency virus, or immune-mediated (autoimmune) disease that requires immunosuppressive therapies (drugs or biologics). The use of topical corticosteroids or other immunosuppressive agents (for example, topical calcineurin inhibitor) may be eligible for participation at the discretion of the Investigator.
- History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine or intervention that includes one or more of the same components contained in the study vaccine.
- Any history of myocarditis or pericarditis.
- Coagulopathy or bleeding disorder considered a contraindication to IM injection or phlebotomy.
- Dermatologic conditions that could affect local solicited AR assessments (for example, tattoos, psoriasis patches affecting skin over the deltoid areas).
- Has received systemic immunosuppressive therapies (drugs or biologics) for >14 days in total within 6 months prior to Screening (for corticosteroids ≥10 mg/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. Inhaled, nasal, intra-articular, and topical steroids are allowed.
- Has received or plans to receive any licensed/authorized vaccine (to include severe acute respiratory syndrome-related coronavirus-2 vaccine) ≤28 days prior to or within 28 days after each study intervention, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study intervention.
- Has received systemic immunoglobulins or blood products within 3 months prior to the Screening Visit or plans for receipt during the study.
- Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
- Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to participate in an interventional clinical trial of an investigational vaccine or drug while participating in this study.
- Phase 2 Part: Individuals who are participating/have participated in the Phase 1 part of the study are excluded.
- Phase 1 Part: Any individual with laboratory abnormalities achieving thresholds defined in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1 Part: mRNA-1403 Dose Level 1
Participants will receive 2 intramuscular (IM) injections of mRNA-1403 at Dose Level 1.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1403 Dose Level 2
Participants will receive 2 IM injections of mRNA-1403 at Dose Level 2.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1403 Dose Level 3
Participants will receive 2 IM injections of mRNA-1403 at Dose Level 3.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1403 Dose Level 4 Regimen 1
Participants will receive 2 IM injections of mRNA-1403 at Dose Level 4.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1403 Dose Level 4 Regimen 2
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
|
0.9% sodium chloride (normal saline) injection
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1405 Dose Level 1
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 1.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1405 Dose Level 2
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 2.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1405 Dose Level 3
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 3.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1405 Dose Level 4 Regimen 1
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 4.
|
Sterile liquid for injection
|
Experimental: Phase 1 Part: mRNA-1405 Dose Level 4 Regimen 2
Participants will receive 1 IM injections of mRNA-1405 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
|
0.9% sodium chloride (normal saline) injection
Sterile liquid for injection
|
Placebo Comparator: Phase 1 Part: Placebo
Participants will receive 2 IM injections of study vaccine-matching placebo.
|
0.9% sodium chloride (normal saline) injection
|
Experimental: Phase 2 Part: mRNA-1403 Dose Level 1
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 1.
|
Sterile liquid for injection
|
Experimental: Phase 2 Part: mRNA-1403 Dose Level 2
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 2.
|
Sterile liquid for injection
|
Experimental: Phase 2 Part: mRNA-1403 Dose Level 3
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 3.
|
Sterile liquid for injection
|
Placebo Comparator: Phase 2 Part: Placebo
Participants will receive 1 IM injection of study vaccine-matching placebo.
|
0.9% sodium chloride (normal saline) injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Time Frame: Up to a maximum of Day 36 (7 days after last study injection)
|
Up to a maximum of Day 36 (7 days after last study injection)
|
Number of Participants with Unsolicited Adverse Events (AEs)
Time Frame: Up to a maximum of Day 57 (28 days after last study injection)
|
Up to a maximum of Day 57 (28 days after last study injection)
|
Number of Participants with Medically Attended AEs (MAAEs)
Time Frame: Day 1 up to a maximum of Day 197
|
Day 1 up to a maximum of Day 197
|
Number of Participants with Any Serious Adverse Events (SAEs), AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine, and Adverse Events of Special Interest (AESIs)
Time Frame: Day 1 up to a maximum of Day 365
|
Day 1 up to a maximum of Day 365
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Geometric Mean Titers (GMT) of Histo-Blood Group Antigen (HBGA) Blocking Antibodies Against Vaccine-matched Norovirus (NoV) Genotypes
Time Frame: Phase 1: Days 1, 29, and 57; Phase 2: Days 1 and 29
|
Phase 1: Days 1, 29, and 57; Phase 2: Days 1 and 29
|
Geometric Mean Fold Rise (GMFR) of HBGA Blocking Antibodies Titers
Time Frame: Phase 1: Days 1, 29, and 57; Phase 2: Days 1 and 29
|
Phase 1: Days 1, 29, and 57; Phase 2: Days 1 and 29
|
Percentage of Participants with Seroresponse Based on HBGA Blocking Antibody Titers
Time Frame: Phase 1: Days 29, and 57; Phase 2: Day 29
|
Phase 1: Days 29, and 57; Phase 2: Day 29
|
Geometric Mean Concentration (GMC) of Binding Antibody (bAb) Against Vaccine-matched NoV Genotypes
Time Frame: Days 1, 29, and 57
|
Days 1, 29, and 57
|
GMFR of bAb Levels
Time Frame: Days 1, 29, and 57
|
Days 1, 29, and 57
|
Percentage of Participants with Seroresponse Based on bAb Levels
Time Frame: Days 29 and 57
|
Days 29 and 57
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 25, 2023
Primary Completion (Estimated)
May 7, 2025
Study Completion (Estimated)
May 7, 2025
Study Registration Dates
First Submitted
August 7, 2023
First Submitted That Met QC Criteria
August 7, 2023
First Posted (Actual)
August 15, 2023
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 26, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- mRNA-1403/1405-P101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Norovirus Acute Gastroenteritis
-
National Institute of Allergy and Infectious Diseases...CompletedGastroenteritis NorovirusUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedGastroenteritis NorovirusUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
National Institute of Allergy and Infectious Diseases...WithdrawnGastroenteritis NorovirusUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Vaccine and Serum Institute, ChinaZhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...RecruitingNorwalk Gastroenteritis | Norovirus InfectionsChina
-
National Vaccine and Serum Institute, ChinaZhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...CompletedNorwalk Gastroenteritis | Norovirus InfectionsChina
-
National Vaccine and Serum Institute, ChinaLanzhou Institute of Biological Products Co., LtdNot yet recruitingNorwalk Gastroenteritis | Norovirus Infections
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States